BPH GLOBAL LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0035 AUD | 0.00% |
|
-12.50% | -53.33% |
| 13/06 | BPH Global Refocusing R&D for Seaweed-Sourced Energy Program | MT |
| 06/06 | BPH Global to Source Bird's Nest Products from China's Sinopharm; Shares Plummet 40% | MT |
| Sales 2022 | 14.35M 9.56M 800M | Sales 2023 | 339 225.87 18.89K | Capitalization | 3.85M 2.57M 215M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -2M -167M | Net income 2023 | -4M -2.67M -223M | EV / Sales 2022 | 1.07 x |
| Net Debt 2022 | 627K 418K 34.92M | Net cash position 2023 | 511K 340K 28.47M | EV / Sales 2023 | 9,862 x |
| P/E ratio 2022 |
-3.97
x | P/E ratio 2023 |
-0.72
x | Employees | 31 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 35.23% |
More Fundamentals
* Assessed data
More news
| 1 week | -12.50% | ||
| Current month | -12.50% | ||
| 1 month | -30.00% | ||
| 3 months | -30.00% | ||
| 6 months | -53.33% | ||
| Current year | -53.33% |
1 week
0.00
0.00
1 month
0.000.01
Current year
0.000.01
1 year
0.000.02
3 years
0.000.11
5 years
0.000.25
10 years
0.005.43
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Leonard
CEO | Chief Executive Officer | 53 | 30/23/30 |
Justyn Stedwell
SEC | Corporate Secretary | - | 11/04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 21/21/21 | |
Paul Stephenson
CHM | Chairman | 63 | 31/20/31 |
Yan Hua Huang
BRD | Director/Board Member | - | 27/19/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 0.0035 | 0.00% | 102 500 |
| 20/24/20 | 0.0035 | 0.00% | 3,400 |
| 19/24/19 | 0.0035 | -12.50% | 142,296 |
| 18/24/18 | 0.004 | 0.00% | 1,377,766 |
| 17/24/17 | 0.004 | 0.00% | 20,166 |
Delayed Quote Australian S.E., June 21, 2024 at 08:03 am IST
More quotes
BPH Global Ltd is a plant-focused biotechnology company. The Company is focused on producing foods and products that deliver Traditional Chinese Medicine-based health outcomes. It focuses on the research and development, production and commercialization of plant-based products, including seaweed and sea plants to produce sustainable plant-based protein foods and nutraceutical and pharmaceutical ingredients (including cannabidiol (CBD) extracted from Hemp) for utilization in the food, nutrition, healthcare, cosmetics, and personal care industries. Its principal business focus is on Singapore, Australia, Southeast Asia, and Chinese markets. The Company produces its products through various plants, which include Caulerpa lentillifera, Dendrobium officinale, Resina and Cannabis sativa. It is also into the sales and distribution of bird's nest products in China. Its subsidiaries include Stemcell United Pte Ltd, Stemcell Essential Pte Ltd, and SCU Southeast Asia Sdn Bhd, SCU (HK) Ltd.
Calendar
28/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -53.33% | 911K | |
| +35.14% | 51.51B | |
| -7.43% | 39.03B | |
| +35.88% | 38.91B | |
| -10.62% | 26.68B | |
| +11.63% | 26.13B | |
| -17.77% | 19.91B | |
| +40.52% | 13.71B | |
| +30.70% | 12.38B | |
| -3.41% | 11.74B |
- Stock Market
- Equities
- BP8 Stock
